K
Khê Hoang-Xuan
Researcher at University of Paris
Publications - 353
Citations - 24999
Khê Hoang-Xuan is an academic researcher from University of Paris. The author has contributed to research in topics: Primary central nervous system lymphoma & Temozolomide. The author has an hindex of 69, co-authored 319 publications receiving 21794 citations. Previous affiliations of Khê Hoang-Xuan include Paris-Sorbonne University & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Olivier Chinot,Wolfgang Wick,Warren P. Mason,Roger Henriksson,Frank Saran,Ryo Nishikawa,Antoine F. Carpentier,Khê Hoang-Xuan,Petr Kavan,Dana Cernea,Alba A. Brandes,Magalie Hilton,Lauren E. Abrey,Timothy F. Cloughesy +13 more
TL;DR: The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma, and the glucocorticoid requirement was lower.
Journal ArticleDOI
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2
Guy A. Rouleau,P. Merel,Mohini Lutchman,Marc Sanson,Marc Sanson,Jessica Zucman,Claude Marineau,Khê Hoang-Xuan,S. Demczuk,Chantal Desmaze,Béatrice Plougastel,Stefan M. Pulst,Gilbert M. Lenoir,E. K. Bijlsma,Raimund Fashold,Jan P. Dumanski,Pieter J. de Jong,Dilys M. Parry,Roswell Eldrige,Alain Aurias,Olivier Delattre,Gilles Thomas +21 more
TL;DR: The deduced product has homology with proteins at the plasma membrane and cytoskeleton Interface, a previously unknown site of action of tumour suppressor genes in humans.
Journal ArticleDOI
Primary brain tumours in adults
TL;DR: High-throughput methods that enable genome-wide analysis of tumours have improved the knowledge of tumour biology, which should lead to a better classification of gliomas and pave the way for so-called targeted therapy trials.
Journal ArticleDOI
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent,Alba A. Brandes,Martin J.B. Taphoorn,Johan M. Kros,Mathilde C.M. Kouwenhoven,Jean-Yves Delattre,Hans J.J.A. Bernsen,Marc Frenay,Cees C. Tijssen,Wolfgang Grisold,László Sipos,Roelien H. Enting,Pim J. French,Winand N.M. Dinjens,Charles J. Vecht,Anouk Allgeier,Denis Lacombe,Thierry Gorlia,Khê Hoang-Xuan +18 more
TL;DR: The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors, and 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/ 19q-deleted tumors.
Journal ArticleDOI
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson,Yannick Marie,Sophie Paris,Ahmed Idbaih,Julien Laffaire,François Ducray,Soufiane El Hallani,Blandine Boisselier,Karima Mokhtari,Khê Hoang-Xuan,Jean-Yves Delattre +10 more
TL;DR: This study indicates that IDH1 codon 132 mutation is closely linked to the genomic profile of the tumor and constitutes an important prognostic marker in grade 2 to 4 gliomas.